A Phase 1 interventional study of Capecitabine and RhuMab 2C4 in Solid Tumor, sponsored by Hoffmann-La Roche. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-11-10.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the safety, tolerability, and pharmacokinetics of the combination of rhuMab 2C4(Perjeta) and capecitabine (Xeloda) in participants with advanced solid tumors that have progressed during or after standard therapy, or for which no standard therapy is available. Participants will be enrolled and evaluated for dose-limiting toxicities (DLTs) in escalating-dose cohorts in order to determine the maximum tolerated dose (MTD).
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single 1000-mg/m\^2 dose of oral (PO) capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 1000 mg/m\^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
Drug: Capecitabine · Drug: RhuMab 2C4
Participants will receive a single 1250-mg/m\^2 dose of PO capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 1250 mg/m\^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
Drug: Capecitabine · Drug: RhuMab 2C4
Participants will receive a single 825-mg/m\^2 dose of PO capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 825 mg/m\^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
Drug: Capecitabine · Drug: RhuMab 2C4
Participants will receive capecitabine on Days 1 to 14 of each 3-week cycle as 825, 1000, or 1250 mg/m\^2 PO twice daily. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
Also known as: Xeloda
Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 1050 mg via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
Also known as: Omnitarg
Maximum Tolerated Dose (MTD) of the Combination of Pertuzumab and Capecitabine
MTD was defined as the highest tolerated dose combination of capecitabine (825 mg, 1000 mg or 1250 mg) and pertuzumab, without causing Dose Limiting Toxicities (DLTs). DLTs were defined as follows: 1) Any non-hematological toxicity greater than or equal to (≥) Grade 3 according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 except for fever, chills and flu-like symptoms, in spite of adequate toxicity management; 2) Grade 4 neutropenia lasting \> 7 days; 3) Febrile neutropenia; 4) Thrombocytopenia Grade 4 or any thrombocytopenia requiring platelet transfusion; 5) Any subjectively intolerable toxicity felt by the investigator to be related to either one of the compounds. Participants who withdrew from the study without completing the first treatment cycle for reasons other than DLT were not considered evaluable for DLT. MTD was measured in mg/m\^2.
Time frame: Cycle 1 (3 Weeks)
Percentage of Participants With DLTs
DLTs were defined as follows: 1)Any non-hematological toxicity greater than or equal to (≥) Grade 3 according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 except for fever, chills and flu-like symptoms, in spite of adequate toxicity management; 2) Grade 4 neutropenia lasting \> 7 days; 3) Febrile neutropenia; 4) Thrombocytopenia Grade 4 or any thrombocytopenia requiring platelet transfusion; 5) Any subjectively intolerable toxicity felt by the investigator to be related to either one of the compounds. Participants who withdrew from the study without completing the first treatment cycle for reasons other than DLT were not considered evaluable for DLT.
Time frame: Cycle 1 (3 Weeks)
Plasma Half-Life (t1/2) of Pertuzumab
The biological half-life or terminal half-life of pertuzumab is the time in days it takes for it to lose half of its pharmacologic activity. t1/2 was measured in days.
Time frame: Cycle 1: Days 2, 5, 8 and 15 Postdose; Cycle 2: Day 1 at drug administration, predose and 15 minutes postdose, and Predose on Days 8, 15 and 22
Maximum Plasma Concentration (Cmax) of Pertuzumab
Cmax refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and prior to the administration of a second dose and was measured as nanograms per milliliter (ng/mL).
Time frame: Cycle 1: Days 2, 5, 8 and 15 Postdose; Cycle 2: Day 1 at drug administration, predose and 15 minutes postdose, and predose on Days 8, 15 and 22
Time to Maximum Plasma Concentration (Tmax) of Pertuzumab
Tmax is defined as the time after administration of a drug when the maximum plasma concentration is reached; when the rate of absorption equals the rate of elimination. Tmax was measured in days.
Time frame: Cycle 1: Days 2, 5, 8 and 15 Postdose; Cycle 2: Day 1 at drug administration, predose and 15 minutes postdose, and predose on Days 8, 15 and 22
Area Under the Concentration Curve From Time Zero to Last Measurement (AUC 0-last) of Pertuzumab
The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-last is calculated from time 0 (prior to administration of medication) to last measured data point. The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC was measured as ng\*day/mL.
Time frame: Cycle 1: Days 2, 5, 8 and 15 Postdose; Cycle 2: Day 1 at drug administration, predose and 15 minutes postdose, and predose on Days 8, 15 and 22
AUC From Time Zero to Infinity (AUC 0-infinity) of Pertuzumab
The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC is measured as nanograms times days per milliliter (ng\*day/mL).
Time frame: Cycle 1: Days 2, 5, 8 and 15 Postdose; Cycle 2: Day 1 at drug administration, predose and 15 minutes postdose, and predose on Days 8, 15 and 22
Apparent Volume of Distribution of Pertuzumab
The volume of distribution at steady state (Vss), also known as apparent volume of distribution, is a pharmacological, theoretical volume that the total amount of administered drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma. Vss was measured in mL
Time frame: Cycle 1: Days 2, 5, 8 and 15 Postdose; Cycle 2: Day 1 at drug administration, predose and 15 minutes postdose, and predose on Days 8, 15 and 22
Apparent Total Clearance of Pertuzumab
Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It is measured as milliliters per day (mL/day).
Time frame: Cycle 1: Days 2, 5, 8 and 15 Postdose; Cycle 2: Day 1 at drug administration, predose and 15 minutes postdose, and predose on Days 8, 15 and 22
Plasma Half-Life of Capecitabine and it's Metabolites When Given Alone and in Combination With Pertuzumab
Capecitabine is a novel oral fluoropyrimidine carbamate that is preferentially converted to the cytotoxic moiety fluorouracil (5-fluorouracil; 5-FU) in target tumour tissue through a series of 3 metabolic steps through the intermediate metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR), 5'-deoxy-5-fluorouridine (5'-DFUR), and α-fluoro-β-alanine (FBAL). The biological half-life or terminal half-life is the time in days it takes for it to lose half of its pharmacologic activity.
Time frame: Day -7: Predose, 30 minutes, 1, 2, 3, 4, 5, 6 and 10 hours postdose; Cycle 1 Day 1: Predose, 0 and 30 minutes, 1, 2, 3, 4, 5, 6 and 10 hours Postdose
Maximum Plasma Concentration of Capecitabine and it's Metabolites When Given Alone and in Combination With Pertuzumab
Capecitabine is an oral fluoropyrimidine carbamate that is preferentially converted to the cytotoxic moiety 5-FU in target tumour tissue through a series of 3 metabolic steps through the intermediate metabolites 5'-DFCR, 5'-DFUR, and FBAL. Cmax refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and prior to the administration of a second dose and is measures as nanograms per milliliter (ng/mL).
Time frame: Day -7: Predose, 30 minutes, 1, 2, 3, 4, 5, 6 and 10 hours postdose; Cycle 1 Day 1: Predose, 0 and 30 minutes, 1, 2, 3, 4, 5, 6 and 10 hours Postdose
Time to Maximum Plasma Concentration of Capecitabine and it's Metabolites When Given Alone and in Combination With Pertuzumab
Capecitabine is a novel oral fluoropyrimidine carbamate that is preferentially converted to the cytotoxic moiety fluorouracil (5-fluorouracil; 5-FU) in target tumour tissue through a series of 3 metabolic steps through the intermediate metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR), 5'-deoxy-5-fluorouridine (5'-DFUR), and α-fluoro-β-alanine (FBAL). Tmax is defined as the time after administration of a drug when the maximum plasma concentration is reached; when the rate of absorption equals the rate of elimination.
Time frame: Day -7: Predose, 30 minutes, 1, 2, 3, 4, 5, 6 and 10 hours postdose; Cycle 1 Day 1: Predose, 0 and 30 minutes, 1, 2, 3, 4, 5, 6 and 10 hours Postdose
| Milestone | Capecitabine 825 Plus (+) Pertuzumab 1050 | Capecitabine 1000 + Pertuzumab 1050 | Capecitabine 1250 + Pertuzumab 1050 |
|---|---|---|---|
| Started | 5 | 7 | 7 |
| Completed | 2 | 2 | 6 |
| Not completed | 3 | 5 | 1 |
| Withdrew: Insufficient therapeutic response | 3 | 3 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Refused treatment | 0 | 1 | 0 |
MTD was defined as the highest tolerated dose combination of capecitabine (825 mg, 1000 mg or 1250 mg) and pertuzumab, without causing Dose Limiting Toxicities (DLTs). DLTs were defined as follows: 1) Any non-hematological toxicity greater than or equal to (≥) Grade 3 according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 except for fever, chills and flu-like symptoms, in spite of adequate toxicity management; 2) Grade 4 neutropenia lasting \> 7 days; 3) Febrile neutropenia; 4) Thrombocytopenia Grade 4 or any thrombocytopenia requiring platelet transfusion; 5) Any subjectively intolerable toxicity felt by the investigator to be related to either one of the compounds. Participants who withdrew from the study without completing the first treatment cycle for reasons other than DLT were not considered evaluable for DLT. MTD was measured in mg/m\^2.
| mg/m^2 | Capecitabine + Pertuzumab |
|---|---|
| Maximum Tolerated Dose (MTD) of the Combination of Pertuzumab and Capecitabine | 1250 |
DLTs were defined as follows: 1)Any non-hematological toxicity greater than or equal to (≥) Grade 3 according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 except for fever, chills and flu-like symptoms, in spite of adequate toxicity management; 2) Grade 4 neutropenia lasting \> 7 days; 3) Febrile neutropenia; 4) Thrombocytopenia Grade 4 or any thrombocytopenia requiring platelet transfusion; 5) Any subjectively intolerable toxicity felt by the investigator to be related to either one of the compounds. Participants who withdrew from the study without completing the first treatment cycle for reasons other than DLT were not considered evaluable for DLT.
| percentage of participants | Capecitabine 825 Plus (+) Pertuzumab 1050 | Capecitabine 1000 + Pertuzumab 1050 | Capecitabine 1250 + Pertuzumab 1050 |
|---|---|---|---|
| Percentage of Participants With DLTs | 0.0 | 0.0 | 0.0 |
The biological half-life or terminal half-life of pertuzumab is the time in days it takes for it to lose half of its pharmacologic activity. t1/2 was measured in days.
| days | Capecitabine + Pertuzumab |
|---|---|
| Plasma Half-Life (t1/2) of Pertuzumab | 14.6 ± 41.0 |
Cmax refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and prior to the administration of a second dose and was measured as nanograms per milliliter (ng/mL).
| ng/mL | Capecitabine + Pertuzumab |
|---|---|
| Maximum Plasma Concentration (Cmax) of Pertuzumab | 355111 ± 59051 |
Tmax is defined as the time after administration of a drug when the maximum plasma concentration is reached; when the rate of absorption equals the rate of elimination. Tmax was measured in days.
| days | Capecitabine + Pertuzumab |
|---|---|
| Time to Maximum Plasma Concentration (Tmax) of Pertuzumab | 0.137 ± 0.076 |
The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-last is calculated from time 0 (prior to administration of medication) to last measured data point. The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC was measured as ng\*day/mL.
| ng*day/mL | Capecitabine + Pertuzumab |
|---|---|
| Area Under the Concentration Curve From Time Zero to Last Measurement (AUC 0-last) of Pertuzumab | 2742561 ± 743598 |
The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC is measured as nanograms times days per milliliter (ng\*day/mL).
| ng*day/mL | Capecitabine + Pertuzumab |
|---|---|
| AUC From Time Zero to Infinity (AUC 0-infinity) of Pertuzumab | 4096501 ± 1282130 |
The volume of distribution at steady state (Vss), also known as apparent volume of distribution, is a pharmacological, theoretical volume that the total amount of administered drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma. Vss was measured in mL
| mL | Capecitabine + Pertuzumab |
|---|---|
| Apparent Volume of Distribution of Pertuzumab | 5202 ± 1007 |
Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It is measured as milliliters per day (mL/day).
| mL/day | Capecitabine + Pertuzumab |
|---|---|
| Apparent Total Clearance of Pertuzumab | 283.0 ± 98.0 |
Capecitabine is a novel oral fluoropyrimidine carbamate that is preferentially converted to the cytotoxic moiety fluorouracil (5-fluorouracil; 5-FU) in target tumour tissue through a series of 3 metabolic steps through the intermediate metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR), 5'-deoxy-5-fluorouridine (5'-DFUR), and α-fluoro-β-alanine (FBAL). The biological half-life or terminal half-life is the time in days it takes for it to lose half of its pharmacologic activity.
| hours | Capecitabine 825 + Pertuzumab 1050 | Capecitabine 1000 + Pertuzumab 1050 | Capecitabine 1250 + Pertuzumab 1050 |
|---|---|---|---|
| Capecitabine Alone 5'-DFCR | 0.89 ± 0.27 | 0.82 ± 0.28 | 0.82 ± 0.23 |
| Capecitabine Alone 5'-DFUR | 0.75 ± 0.26 | 0.76 ± 0.23 | 0.66 ± 0.09 |
| Capecitabine Alone 5-FU | 0.67 ± 0.22 | 0.64 ± 0.13 | 0.70 ± 0.16 |
| Capecitabine Alone Capecitabine | 0.54 ± 0.19 | 0.40 ± 0.10 | 0.36 ± 0.11 |
| Capecitabine Alone FBAL | 2.54 ± 0.30 | 2.69 ± 0.39 | 3.08 ± 0.78 |
| Capecitabine + Pertuzumab 5'-DFCR | 0.78 ± 0.38 | 0.76 ± 0.18 | 0.75 ± 0.14 |
| Capecitabine + Pertuzumab 5'-DFUR | 0.62 ± 0.13 | 0.73 ± 0.21 | 0.79 ± 0.28 |
| Capecitabine + Pertuzumab 5-FU | 0.73 ± 0.40 | 0.67 ± 0.14 | 0.80 ± 0.35 |
| Capecitabine + Pertuzumab Capecitabine | 0.42 ± 0.14 | 0.62 ± 0.28 | 0.54 ± 0.28 |
| Capecitabine + Pertuzumab FBAL | 2.59 ± 0.64 | 2.58 ± 0.57 | 2.81 ± 0.44 |
Capecitabine is an oral fluoropyrimidine carbamate that is preferentially converted to the cytotoxic moiety 5-FU in target tumour tissue through a series of 3 metabolic steps through the intermediate metabolites 5'-DFCR, 5'-DFUR, and FBAL. Cmax refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and prior to the administration of a second dose and is measures as nanograms per milliliter (ng/mL).
| ng/mL | Capecitabine 825 + Pertuzumab 1050 | Capecitabine 1000 + Pertuzumab 1050 | Capecitabine 1250 + Pertuzumab 1050 |
|---|---|---|---|
| Capecitabine Alone 5'-DFCR | 4508 ± 2317 | 7687 ± 1443 | 8647 ± 3254 |
| Capecitabine Alone 5'-DFUR | 5274 ± 1832 | 7657 ± 2708 | 10311 ± 3323 |
| Capecitabine Alone 5-FU | 201 ± 94 | 355 ± 119 | 369 ± 107 |
| Capecitabine Alone Capecitabine | 4802 ± 3159 | 9112 ± 6189 | 7543 ± 2944 |
| Capecitabine Alone FBAL | 3214 ± 396 | 3963 ± 947 | 5290 ± 576 |
| Capecitabine + Pertuzumab 5'-DFCR | 4909 ± 2518 | 3917 ± 1411 | 6569 ± 2827 |
| Capecitabine + Pertuzumab 5'-DFUR | 5736 ± 1831 | 4103 ± 1595 | 8683 ± 4142 |
| Capecitabine + Pertuzumab 5-FU | 219 ± 106 | 187 ± 92 | 345 ± 214 |
| Capecitabine + Pertuzumab Capecitabine | 8060 ± 4800 | 3367 ± 1741 | 4731 ± 3198 |
| Capecitabine + Pertuzumab FBAL | 3674 ± 1121 | 3498 ± 809 | 5136 ± 843 |
Capecitabine is a novel oral fluoropyrimidine carbamate that is preferentially converted to the cytotoxic moiety fluorouracil (5-fluorouracil; 5-FU) in target tumour tissue through a series of 3 metabolic steps through the intermediate metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR), 5'-deoxy-5-fluorouridine (5'-DFUR), and α-fluoro-β-alanine (FBAL). Tmax is defined as the time after administration of a drug when the maximum plasma concentration is reached; when the rate of absorption equals the rate of elimination.
| hours | Capecitabine 825 + Pertuzumab 1050 | Capecitabine 1000 + Pertuzumab 1050 | Capecitabine 1250 + Pertuzumab 1050 |
|---|---|---|---|
| Capecitabine Alone 5'-DFCR | 1.3 ± 0.66 | 0.82 ± 0.26 | 1.05 ± 0.51 |
| Capecitabine Alone 5'-DFUR | 1.3 ± 0.66 | 0.76 ± 0.49 | 1.05 ± 0.51 |
| Capecitabine Alone 5-FU | 1.3 ± 0.66 | 0.64 ± 0.49 | 1.05 ± 0.51 |
| Capecitabine Alone Capecitabine | 1.2 ± 0.75 | 0.4 ± 0.28 | 0.77 ± 0.35 |
| Capecitabine Alone FBAL | 2.4 ± 0.55 | 2.69 ± 0.41 | 2.21 ± 0.40 |
| Capecitabine + Pertuzumab 5'-DFCR | 0.9 ± 0.65 | 1.42 ± 0.66 | 1.86 ± 1.32 |
| Capecitabine + Pertuzumab 5'-DFUR | 1.0 ± 0.61 | 2.0 ± 1.10 | 1.86 ± 1.32 |
| Capecitabine + Pertuzumab 5-FU | 0.9 ± 0.65 | 1.84 ± 1.17 | 1.93 ± 1.24 |
| Capecitabine + Pertuzumab Capecitabine | 0.7 ± 0.28 | 1.17 ± 0.40 | 1.15 ± 0.62 |
| Capecitabine + Pertuzumab FBAL | 2.6 ± 0.90 | 3.16 ± 1.17 | 2.50 ± 1.39 |
Collected over Adverse events were recorded continuously from Day -7 until 4 weeks after the final visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Capecitabine 825 + Pertuzumab 1050 | — | 0/5 (0%) | 5/5 (100%) |
| Capecitabine 1000 + Pertuzumab 1050 | — | 1/6 (16.7%) | 6/6 (100%) |
| Capecitabine 1250 + Pertuzumab 1050 | — | 1/7 (14.3%) | 7/7 (100%) |
| Event | Capecitabine 825 + Pertuzumab 1050 | Capecitabine 1000 + Pertuzumab 1050 | Capecitabine 1250 + Pertuzumab 1050 |
|---|---|---|---|
| Intestinal ObstructionGastrointestinal disorders | 0/5 | 1/6 | 0/7 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 0/5 | 0/6 | 1/7 |
| Event | Capecitabine 825 + Pertuzumab 1050 | Capecitabine 1000 + Pertuzumab 1050 | Capecitabine 1250 + Pertuzumab 1050 |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/5 | 3/6 | 7/7 |
| NauseaGastrointestinal disorders | 4/5 | 4/6 | 4/7 |
| AstheniaGeneral disorders | 1/5 | 3/6 | 4/7 |
| Mucosal inflammationGeneral disorders | 0/5 | 2/6 | 4/7 |
| AnorexiaMetabolism and nutrition disorders | 2/5 | 3/6 | 4/7 |
| Keratoconjunctivitis siccaEye disorders | 0/5 | 0/6 | 4/7 |
| VomitingGastrointestinal disorders | 2/5 | 3/6 | 2/7 |
| ConstipationGastrointestinal disorders | 0/5 | 0/6 | 3/7 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 0/5 | 0/6 | 3/7 |
| InsomniaPsychiatric disorders | 0/5 | 0/6 | 3/7 |
The Intent-To-Treat (ITT) Population included all participants who received any amount of the study medication. The baseline analysis population represents participants from all three cohorts.
| Age, Continuous(years) | Capecitabine + Pertuzumab |
|---|---|
| Mean | 60.9 ± 9.10 |
| Sex: Female, Male(Participants) | Capecitabine + Pertuzumab |
|---|---|
| Female | 11 |
| Male | 7 |
The record gives a start of Jan 2004, a primary completion of Sep 2005 and a completion of Sep 2005. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 10 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pertuzumab